

TECHNICAL MANUAL

ADCC Bioassay Effector Cells, Propagation Model

Instructions for Use of Product
G7102



ADCC Bioassay Effector Cells, Propagation Model

All technical literature is available at: www.promega.com/protocols/
 Visit the web site to verify that you are using the most current version of this Technical Manual.
 E-mail Promega Technical Services if you have questions on use of this system: techserv@promega.com

1. Description.....	2
2. Product Components and Storage Conditions	7
3. Before You Begin.....	7
3.A. Materials to Be Supplied by the User	8
3.B. Composition of Required Media and Buffers	9
4. Preassay Cell Procedures for ADCC Bioassay Effector Cells, Propagation Model.....	9
4.A. Thawing and Initial Culture Procedure for ADCC Bioassay Effector Cells, Propagation Model	9
4.B. Propagation of ADCC Bioassay Effector Cells	9
4.C. Freezing Cells to Create Cell Banks	10
5. Protocol for ADCC Bioassay Effector Cells, Propagation Model	10
5.A. Preparation of Components, Reagents and Bioassay Starting Materials.....	12
5.B. Plate Layout Design	12
5.C. Preparing and Plating Target Cells	13
5.D. Preparing Antibody Serial Dilutions.....	14
5.E. Preparing ADCC Bioassay Effector Cells	16
5.F. Adding Antibody and ADCC Bioassay Effector Cells to Target Cells in Assay Plates.....	16
5.G. Adding Bio-Glo™ Luciferase Assay Reagent	16
5.H. Data Analysis	17
6. Troubleshooting.....	17
7. References.....	19
8. Composition of Buffers and Media	20
9. Appendix: Representative Assay Results	20
10. Related Products.....	21
11. Summary of Changes	22



1. Description

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism of action of antibodies through which virus-infected or other diseased cells are targeted for destruction by components of the cell-mediated immune system, such as natural killer cells. The ADCC Reporter Bioassay is a bioluminescent reporter assay for quantifying biological activity on pathway activation by therapeutic antibody drugs in an ADCC mechanism of action (MOA) assay. The ADCC Reporter Bioassay can be performed with the ADCC Bioassay Effector Cells, Propagation Model^(a-c) (Cat.# G7102), described here, a model that allows cell banking and propagation under a unique purchase agreement. The assay combines a simple, add-mix-read format and an optimized protocol to provide a bioassay that has low variability and high accuracy. These performance characteristics make the bioassay suitable for application across antibody drug research, development and manufactured lot release.

A note on kit formats: We offer the ADCC Reporter Bioassay technology in multiple kit formats to better meet research needs. The ADCC Reporter Bioassay, Core Kit (Cat.# G7010 and G7018) contains the key reagent components (ADCC Bioassay Effector Cells, RPMI 1640 Medium, Low IgG Serum, Bio-Glo™ Luciferase Assay System) needed to perform an ADCC Reporter Bioassay with user-provided specific target cells and antibody. The ADCC Reporter Bioassay, Complete Kits [Cat.# G7014 (WIL2-S), Cat.# G7015 (Raji)] serve as starter kits or are for use with specific B-cell targets; they contain all reagent components needed to perform the bioassay. Target Kits contain Target Cells [WIL2-S (Cat.# G7013) or Raji (Cat.# G7016)] and Control Ab, Anti-CD20, and can be used with Core Kits if desired, providing flexibility to the end user. A Core Kit and a Target Kit together, which includes the six reagent components, are equivalent to a Complete kit.

ADCC is a desirable mechanism for killing target cancer cells using antibody-based drugs. The antibody binds to target antigens on the cell surface. When the Fc effector portion of target-bound antibodies also binds to FcγRIIIa receptors on the cell surface of effector cells (natural killer cells predominantly), multiple cross-linking of the two cell types occurs, leading to pathway activation of ADCC MOA (1). Killing of target cells is an endpoint of this pathway activation and is used in classic ADCC bioassays, which use donor peripheral blood mononuclear cells (PBMCs) or the natural killer (NK) cell subpopulation as effector cells (2). These cells can be highly variable in response, are tedious to prepare and can result in high background readings.

The ADCC Bioassay Effector Cells, Propagation Model (Cat# G7102) uses an alternative readout at an earlier point in ADCC MOA pathway: the activation of gene transcription through the NFAT (nuclear factor of activated T-cells) pathway in the effector cell (3,4). Antibody biological activity in ADCC MOA is quantified through the luciferase produced as a result of NFAT pathway activation; luciferase activity in the effector cell is quantified with luminescence readout (Figure 1). Signal is high, and assay background is low. The assay consists of ADCC Bioassay Effector Cells which are Jurkat T cells engineered to express FcγRIIIa receptor, V158 (high affinity) variant, and an NFAT response element driving expression of firefly luciferase (NFAT-RE).




Figure 1. Representation of the ADCC Reporter Bioassay. Readout is luminescence signal from NFAT response element driving expression of firefly luciferase.

The ADCC Reporter Bioassay exhibits the clear specificity desired for a bioassay, as shown in Figure 2. A good assay response is only obtained when target cells with the correct surface antigen, the correct specific antibody, and effector cells expressing FcγRIIIa are present. If any one of these is missing, there is no response.

1. Description (continued)

Target cells, effector cells and specific antibody

- WIL2-S, Jurkat/NFAT-*luc* + Fc γ R1IIa, rituximab
- No target cells ● NO WIL2-S, Jurkat/NFAT-*luc* + Fc γ R1IIa, rituximab
- No effector cells or no Fc γ R1IIa { ▲ WIL2-S, Jurkat/NFAT-*luc* (NO Fc γ R1IIa), rituximab
- ▲ WIL2-S, NO Jurkat/NFAT-*luc* + Fc γ R1IIa, rituximab
- No antibody or nonspecific antibody { ▼ WIL2-S, Jurkat/NFAT-*luc* + Fc γ R1IIa, NO rituximab
- ▼ WIL2-S, Jurkat/NFAT-*luc* + Fc γ R1IIa, trastuzumab




Figure 2. Specificity of the ADCC Reporter Bioassay. Serial dilutions of rituximab (anti-CD20 chimeric monoclonal antibody drug), trastuzumab (anti-Her2 humanized monoclonal antibody drug), or assay medium control (no antibody) were induced for 6 hours at 37°C with engineered Jurkat effector cells (ADCC Bioassay Effector Cells), with or without ADCC Bioassay Target Cells (WIL2-S), as indicated. These data were generated using frozen, thaw-and-use cells. Luciferase activity was quantified using Bio-Glo™ Reagent. Data were fitted to a 4PL curve using GraphPad Prism® software.

The ADCC Reporter Bioassay has performance characteristics suitable for many applications of a bioassay used across antibody drug discovery, development and manufacture: It is stability-indicating and has the precision and accuracy suitable for a lot-release bioassay (Figure 3). Additionally, the assay can be used to quantify effects of glycosylation differences on Fc effector function of antibodies in ADCC MOA (Figure 4), which would be useful for ADCC efficiency variant analysis, for example (5). Benchmarking studies demonstrate the ADCC Reporter Bioassay provides antibody activity ranking equivalent to a classic ADCC bioassay using PBMCs and LDH release as a measure of target cell death (Figure 5).

Parameter		Results	
		WIL2-S Target cells	Raji Target cells
Accuracy	% Expected Relative Potency	% Recovery	% Recovery
	50	97.7	101.0
	75	88.5	101.2
	125	98.4	93.8
	150	98.4	96.7
Repeatability (%CV)	(100% Reference)	5.0	9.1
Intermediate Precision (%CV)		7.3	3.0
Linearity (r^2)		0.995	0.997
Linearity ($y = mx + b$)		$y = 1.016x - 0.052$	$y = 0.922x + 5$

Figure 3. Bioassay characterization. The ADCC Reporter Bioassay was characterized in studies that evaluated accuracy, repeatability, intermediate precision and linearity across the 50–150% relative potency range. Dilution ranges for Control Ab, Anti-CD20, were selected to ensure good coverage of upper and lower asymptotes and sufficient points in the intermediate dose-range for accurate slope and EC_{50} determinations. A series of relative potency samples, of 50%, 75%, 125% and 150% theoretical relative potency, were evaluated as triplicate dilution series of antibody dose on each of 3 different days. The effector-to-target cell ratio (E:T ratio) was 6:1. The ADCC Reporter Bioassay was characterized using ADCC Bioassay Target Cells (WIL2-S) and ADCC Bioassay Target Cells (Raji). These data were generated using thaw-and-use cells. The data were fitted to a 4PL curve, and relative potencies were calculated after parallelism determination using SAS Institutes, Inc. JMP® software. Relative potencies were calculated using the 100% reference sample run as a triplicate dilution series in the same assay plate as the test sample.

1. Description (continued)




Figure 4. Detection of antibody glycosylation. Rituximab-blended samples containing mixtures of fully deglycosylated and fully N-glycosylated antibody were assayed in the ADCC Reporter Bioassay against a 100% relative activity reference sample of fully N-glycosylated rituximab in the same plate. A dose-response curve was generated for each antibody sample. Target cells were ADCC Bioassay Target Cells (WIL2-S), and the E:T ratio was 6:1. These data were generated using frozen thaw-and-use cells. Biological activity was expressed relative to the 100% control run in the same assay plate and plotted against the % of N-glycosylation present. Linear regression analysis was performed to determine correlation.




Figure 5. Antibody biological activity correlated with antibody glycosylation in an ADCC reporter assay and a classic PBMC-based ADCC assay. Blended antibody samples containing 10%, 20%, 30%, 40% or 50% of untreated trastuzumab (fully glycosylated) were prepared by mixing untreated and PNGase F-treated trastuzumab in appropriate proportions. Each of the blended trastuzumab samples was then assayed in triplicate against an untreated trastuzumab (reference sample) in the same plate using an ADCC reporter assay or a PBMC-based ADCC assay. Freshly cultured HER2⁺ SK-BR-3 cells were used as target cells in both assays. For the ADCC reporter assay, the E:T ratio was 15:1 and induction time was 6 hours. Results are mean $\pm$ SD of three independent experiments using the same batch of frozen, thaw-and-use Jurkat effector cells. For the PBMC-based ADCC assay, the effector cells were PBMCs from the donors with Fc γ RIIIa V/V genotype for aa 158 and the E:T ratio was 50:1. After an overnight incubation, target cell lysis was measured by detecting the release of lactate dehydrogenase from lysed SK-BR-3 cells using CytoTox 96[®] Non-Radioactive Cytotoxicity Assay. Results are mean $\pm$ SD of three independent experiments using PBMCs isolated from different donors. Percent ADCC biological activity is defined as the ratio of the EC₅₀ of untreated trastuzumab (N-glycosylated) to the EC₅₀ of the blended trastuzumab mixture in the same assay plate.

2. Product Components and Storage Conditions

Product	Size	Cat.#
ADCC Bioassay Effector Cells, Propagation Model	2 vials	G7102

Not for Medical Diagnostic Use.

Includes: Two vials at 2×10^7 cells/ml and 1ml/vial. One vial should be thawed, propagated and cells frozen to create a cell bank. The remaining vial should be reserved as backup.

Storage Conditions: Upon arrival, immediately transfer vials of ADCC Bioassay Effector Cells for long-term storage below -140°C (freezer or liquid nitrogen vapor phase). For safety reasons do not store cell vials submerged in liquid nitrogen.

3. Before You Begin

Please read through the entire protocol to become familiar with the components and the assay procedure before beginning.

Remove the product label from the box containing vials with cells or note the catalog number and lot number from the label. This information can be used to download documents from the specified product from the website such as Certificate of Analysis.

The ADCC Reporter Bioassay with ADCC Bioassay Effector Cells, Propagation Model, differs from classic ADCC assays in a number of ways. **Please read through the entire protocol for this system to become familiar with the assay, the components and the protocol in general before beginning.** The ADCC Bioassay Effector Cells, Propagation Model, should be handled as described for initial culture and for propagation as described in Section 4. Cell seeding densities and propagation cell density range have been selected to provide good assay performance and consistency. Cell freezing protocols also are described in Section 4, and should be followed carefully.

The effector:target (E:T) cell ratio, the cell number per well for target and effector cells, the antibody dose range, assay buffer and incubation times may differ from those used in a classic ADCC assay with PBMCs or natural killer cells as effector cells. **We recommend that you evaluate these parameters rigorously and select the best conditions for your target system.**

Because the ADCC Reporter Bioassay produces a bioluminescent readout, the assay requires a sensitive luminometer or luminescence plate reader for the detection of signal. See Related Products, Section 10, for a list of GloMax[®] Detection Systems available from Promega. The bioassay produces a strong signal; therefore, an integration time of 0.5 seconds/well should be sufficient. If your luminometer/plate reader requires gain adjustment for luminescence, use the well with the highest Ab concentration. Finally, if you have the ability to select the multiwell plate type in your plate reader software and that multiwell plate is not listed in the software, a generic 96-well plate selection will suffice. We recommend white, flat-bottom 96-well assay plates (Corning Cat.# 3917).



3.A. Materials to Be Supplied by the User

(Composition of buffers and media are provided in Sections 3.B and 8.)

Reagents

- RPMI 1640 with L-glutamine and HEPES (Gibco Cat.# 22400)
- fetal bovine serum (HyClone Cat.# SH30070.03)
- super low IgG FBS (HyClone Cat.# SH30898)
- DPBS (Gibco Cat.# 14190)
- hygromycin (Gibco Cat.# 10687-010)
- Antibiotic G-418 Sulfate Solution (Cat.# V8091)
- sodium pyruvate (Gibco Cat.# 11360)
- MEM nonessential amino acids (Gibco Cat.# 1114)
- DMSO (Sigma Cat.# D2650)
- Trypan Blue solution (Sigma Cat.# T8154)
- monoclonal antibody or derivative with Fc effector function
- user-defined target cells expressing target antigen recognized by the mAb or derivative
- Bio-Glo™ Luciferase Assay System (Cat.# G7940, G7941)

Supplies and Equipment

- bottles for preparation of media and buffer [We recommend Nalgene square media bottles (PETG).]
- sterile clear 96-well, V-bottom plate with lid (Linbro Cat.# 76-223-05 or equivalent) for preparing antibody dilutions
- white, flat-bottom 96-well assay plates (Corning Cat.# 3917 or equivalent)
- pipettes (single channel and 12-channel)
- sterile 15ml and 50ml conical tubes
- sterile reagent reservoirs (Corning Cat.# 4870 or equivalent)
- 37°C CO₂ incubator
- 37°C water bath
- plate reader with glow luminescence read capability or luminometer (e.g., GloMax® Discover Multimode Microplate Reader)
- cryogenic vials

3.B. Composition of Required Media and Buffers

Cell Growth Medium

90%	RPMI 1640 with L-glutamine
10%	FBS
100µg/ml	hygromycin
250µg/ml	Antibiotic G-418 Sulfate Solution
1mM	sodium pyruvate
0.1mM	MEM nonessential amino acids

Cell Freezing Medium

85%	RPMI 1640 with L-glutamine
10%	FBS
5%	DMSO

ADCC Assay Buffer

99.5%	RPMI 1640 with L-glutamine
0.5%	low IgG FBS

4. Preassay Cell Procedures for ADCC Bioassay Effector Cells, Propagation Model

4.A. Thawing and Initial Culture Procedure for ADCC Bioassay Effector Cells, Propagation Model

1. Rapidly thaw the cells by placing cryovials in a 37°C water bath with gentle agitation for 1–2 minutes.
2. Decontaminate the vial by wiping with 70% ethanol before opening in a class II biological safety cabinet.
3. Gently transfer the contents of the vial into 10ml of Cell Growth Medium in a sterile 15ml conical tube.
4. Centrifuge cells at **90 × g for 10 minutes** at ambient temperature.
Note: Higher speeds may reduce cell viability.
5. Aspirate the supernatant, and resuspend the cell pellet in 10ml of Cell Growth Medium (prewarmed to 37°C).
6. Transfer resuspended cells to a T75 flask, and add 5ml of prewarmed Cell Growth Medium for initial culture volume of **15ml** in a T75 flask. Place flasks horizontally, and allow the cells to grow 2–3 days at 37°C and 5% CO₂ in a humidified incubator and monitor cell density until it reaches 1.2–1.8 × 10⁶ cells/ml.
Note: Lower culture volumes may reduce cell viability.

4.B. Propagation of ADCC Bioassay Effector Cells

For subculture, we recommend a cell seeding density of 2.5–4 × 10⁵ cells/ml and maintaining cells in Cell Growth Medium in the range of **2.5 × 10⁵ cells/ml to 2 × 10⁶ cells/ml**. For two-day passage, we recommend seeding at **4 × 10⁵ cells/ml**, and for three-day passage, we recommend seeding at **2.5 × 10⁵ cells/ml**. The culture can be maintained by addition of fresh Cell Growth Medium to the cell suspension in a new flask while keeping the culture volume to flask surface area ratio consistent for each size of propagation flask (**25ml** total culture per T75 flask, or 50ml total culture per T150 flask). Always keep flasks in a **horizontal** position in the CO₂ incubator during culture.

Note: Changing culture volumes, seeding densities or propagation density range may affect cell growth rate and performance of the cells in the assay.

4.B. Propagation of ADCC Bioassay Effector Cells (continued)

1. Determine cell density in the flask after 2–3 days in culture, and include Trypan blue staining during counting to monitor cell viability.
2. Determine appropriate volume of cell suspension to use, based on seeding density at $2.5\text{--}4 \times 10^5$ cells per milliliter, and transfer this volume of cells to a new flask.
3. Add appropriate volume of fresh Cell Growth Medium to the flask to achieve the desired volume.
4. Place flasks horizontally in a 5% CO₂, 37°C humidified incubator.

Note: Wait to use cells in an ADCC bioassay or for cell banking until the cell doubling rate has stabilized, which should occur within 7–10 days. We recommend that you demonstrate stabilization across two consecutive doublings. The typical stabilized doubling rate is 24 ± 8 hours. Passage number should be recorded for each passage. Cells will maintain their functionality for 25 passages (or 58 doublings if passaging is performed on a 2-day/2-day/3-day repeating schedule). Typical viability is 95% during propagation.

4.C. Freezing Cells to Create Cell Banks

1. Determine cell density, and include Trypan blue staining during counting for viability determination.
2. Transfer cell suspension to a 50ml conical tube, and pellet cells at $130 \times g$ for 10 minutes at room temperature.
3. Resuspend cells in 1X DPBS, and recentrifuge at $130 \times g$ for 10 minutes.
4. Resuspend cells in appropriate volume of Cell Freezing Medium (prechilled on ice) so that the final cell density is 5×10^6 cells/ml.
5. Dispense 1.0ml cells per cryogenic vial.
6. Freeze cells using a controlled-rate freezer following a recommended program for vials. Alternatively, place vials in a suitable container (e.g., Mr. Frosty, Thermo Scientific/Nalgene, Cat.# 5100-0001) for slow cooling, and store overnight at -80°C .
7. Transfer vials to a -140°C freezer or into a liquid nitrogen storage tank, and store cells in the vapor phase of liquid nitrogen.

5. Protocol for ADCC Bioassay Effector Cells, Propagation Model

Our recommended protocol for using the Propagation Model cells, described here as an example protocol, is designed to test two antibody samples in a single assay run. Each test antibody and a reference antibody are run in triplicate in 10-point dilution series in a single 96-well assay plate using the same target cells for a total of two plates. Other protocols and plate layouts are possible and may need to be optimized for your specific target antibody and cells.

To routinely use the ADCC Bioassay Effector Cells, Propagation Model, with the antibody and target cell line of your choice in the ADCC Reporter Bioassay, we recommend first optimizing the E:T ratio, by fixing the ADCC Bioassay Effector Cells at 150,000 per well for a 96-well plate and varying the cell number of the target cells. You should establish an E:T ratio that gives a good signal response. You also may need to optimize the dose-range of antibody and serial dilutions of antibody you use to achieve a full dose-response curve with proper upper and lower asymptotes and

sufficient points in the middle of the dose range to achieve reliable values for the fitted slope and the EC_{50} . Induction for 16–24 hours is a good starting place for the assay and has given optimal results for most antibodies we have tested. You can vary the induction time in a range of 6–24 hours to determine the optimal induction time for your antibody. These parameters may differ from those used in a classic ADCC assay with PBMCs or NK cells as effector cells. We recommend that you evaluate these parameters rigorously and select the best conditions for your target system.




Figure 6. Schematic protocol for the ADCC Reporter Bioassay. For the Cell Propagation Model, we recommend 16–24 hours for induction.

5.A. Preparation of Components, Reagents and Bioassay Starting Materials

1. **Bio-Glo™ Luciferase Assay Reagent:** Prepare an appropriate amount of Bio-Glo™ Luciferase Assay Reagent according to the manufacturer's instructions the day before starting the assay. Thaw the Bio-Glo™ Luciferase Assay Buffer in a room-temperature water bath, and equilibrate Bio-Glo™ Luciferase Assay Substrate to ambient temperature, protected from light. Transfer the buffer into the amber bottle containing the Substrate, and mix by inversion until the Substrate is thoroughly dissolved. Make 10ml aliquots of reconstituted Bio-Glo™ Luciferase Assay Reagent, and store at –20°C for up to 6 weeks. Avoid frequent freeze-thaw cycles.

For the assay, thaw the appropriate amount of reconstituted Bio-Glo™ Luciferase Assay Reagent in a room-temperature water bath at least 1–2 hours before use on the day of assay. For your reference, 10ml of Bio-Glo™ Luciferase Assay Reagent is enough for 120 assay wells in a 96-well assay format. Approximate stability of Bio-Glo™ Luciferase Assay Reagent after reconstitution: 18% loss of luminescence over 24 hours at ambient temperature.

2. **ADCC Assay Buffer:** Prepare the appropriate amount of ADCC Assay Buffer first thing on the day of the assay. Thaw the low IgG FBS in a 37°C water bath, and add to RPMI 1640 medium to make ADCC Assay Buffer (RPMI 1640/0.5% low IgG FBS). Mix well and warm to 37°C prior to use. For your reference, 35–50ml of ADCC Assay Buffer is enough for 120 wells in 96-well assay format.

Note: The recommended ADCC Assay Buffer contains 0.5% low IgG FBS. This works well for the majority of target cells that we have tested in ADCC Reporter Bioassay. If you experience any target cell viability or assay performance issues with this ADCC Assay Buffer, we suggest that you test several other serum concentrations (in the range 0.5–10%) to determine the optimal serum concentration for your test antibody and target cells.

3. **Starting dilutions (dilu1, 3X final concentration) for Reference antibody and two Test antibodies:** Decide the starting concentration (1X) for reference antibody and two test antibody samples based on previous testing results in conventional ADCC cytotoxicity assay if available. If the working concentration of test antibody is unknown, use 1µg/ml as starting concentration, and adjust later based on the assay results; this concentration has worked for both rituximab and trastuzumab in the ADCC Reporter Bioassay.

Make 400µl of starting dilution for reference antibody (dilu1, 3X final concentration) and make 200µl of starting dilution for each of the test antibodies (dilu1, 3X final concentration). Use ADCC Assay Buffer to prepare and dilute antibodies in 1.5ml microcentrifuge tubes. Store the tubes containing the antibody starting dilutions appropriately before making antibody serial dilutions.

5.B. Plate Layout Design

We recommend orienting samples within an assay plate in a non-clustered fashion to help minimize any well positional effects on the response. For the protocol we describe here, use the plate layouts in Figure 7 as a guide. **The protocol uses serial replicate dilutions (n = 3) of reference antibody and each of the test antibodies to generate two 10-point dose-response curves in each plate.**

Recommended Plate Layout Design													
	1	2	3	4	5	6	7	8	9	10	11	12	
A	B	B	B	B	B	B	B	B	B	B	B	B	Assay Buffer (B)
B	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
C	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
D	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
E	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
F	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
G	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
H	B	B	B	B	B	B	B	B	B	B	B	B	Assay Buffer (B)

Figure 7. Example plate layout showing non-clustered sample locations of reference antibody dilution series, a single test antibody dilution series, and ADCC Assay Buffer control, color coded for location.

5.C. Preparing and Plating Target Cells

Recommendations for Plating Target Cells

To prepare the target cells for use with the ADCC Bioassay Effector Cells, Propagation Model, the cells need to be cultured using standard practices to maintain viability of cells and density in a range satisfactory for good performance in a conventional ADCC assay. Several suspension target cell lines and adherent target cell lines grown in continuous culture have been tested in the ADCC Reporter Bioassay and demonstrated good results (see Figures 9 and 10).

As a possible alternative that may fit your needs, we have identified appropriate cell growth and freezing conditions that allow specific target cells to be used directly in bioassay without cell culture after thaw. Two suspension B-cell lines (WIL2-S and Raji) have been prepared in frozen, thaw-and-use formats and have demonstrated good results in the ADCC Reporter Bioassay. These Target B-cell lines are currently available from Promega as components in ADCC Reporter Bioassay, Target Kits [Cat. # G7013 (WIL2-S) and Cat. # G7016 (Raji)] or ADCC Reporter Bioassay Complete Kits [Cat. # G7014 (WIL2-S) or Cat. # G7015 (Raji)]. If your target is expressed on these cells you have the option to use one of the frozen, thaw-and-use target cell lines as provided in these kits.

For assay optimization, try E:T ratios in the range of 2.5:1 to 25:1. Keep the cell density of the ADCC Bioassay Effector cells constant, and vary the cell density of the target cells. As a reference, we use 150,000 cells per well for ADCC Bioassay Effector Cells and an E:T ratio of 6:1 when working with ADCC Bioassay Target Cells and an anti-CD20 antibody.

The target cells are the first assay component added to the assay plate in the ADCC Reporter Bioassay. Antibody is added next, then the ADCC Bioassay Effector Cells. Assay plates are then incubated for induction of reporter gene expression.

5.C. Preparing and Plating Target Cells (continued)

Preparation and plating of suspension target cell lines from continuous culture: On the day of assay, first estimate the target cell numbers needed. Harvest enough target cells (two to three times the required cell number) by centrifugation at $130\text{--}200 \times g$ for 10 minutes, wash cells once with 10ml of DPBS, and recentrifuge. Resuspend cells in ADCC Assay Buffer (prewarmed to 37°C) to give a cell volume of approximately 70% of the final required and to provide the appropriate cell density that results in the required target cell number in $25\mu\text{l}$ in each assay well. Count the cells, and evaluate the viability using Trypan Blue staining. After cell counting, adjust the volume of cells to generate the cell density you need for bioassay. Transfer the cell suspension to a sterile reagent reservoir. Using a multichannel pipette immediately add $25\mu\text{l}$ of cells to the inner 60 wells of white 96-well assay plates. Dispense $75\mu\text{l}$ of ADCC Assay Buffer into outermost wells, labeled “B” in Figure 7. Cover plates with lids, and keep the plates in a $5\% \text{CO}_2$ tissue culture incubator at 37°C before adding antibody dilutions and ADCC Bioassay Effector Cells.

Preparation and plating of adherent target cell lines from continuous culture: Twenty to twenty four hours before the assay, remove the cells from the propagation flasks by trypsinization (or other standard procedure), and resuspend the cells in the appropriate volume of fresh culture medium. Count the cells and evaluate cell viability using Trypan Blue. Centrifuge cells at $130\text{--}200 \times g$ (depending on established conditions for your target cells). Resuspend cells in fresh culture medium at an appropriate cell density, so that there will be the appropriate cell number required for each well in the ADCC bioassay when you plate $100\mu\text{l}$ cells per well. Transfer the cells to a sterile reagent reservoir and immediately add $100\mu\text{l}$ of cells to the inner 60 wells of white 96-well assay plates using a multichannel pipette. Dispense $100\mu\text{l}$ of culture medium into those outermost wells, labeled “B” in Figure 7. Place lids on the plates, and incubate overnight in a CO_2 incubator at 37°C .

On the morning of the assay, use a multichannel pipette to remove $95\mu\text{l}$ of culture medium from each of the wells. Add $25\mu\text{l}$ per well of ADCC Assay Buffer (prewarmed to 37°C) to the inner 60 wells of both assay plates. Always allow the pipette tips to touch the wall of the well, and add buffer gently to the wells to minimize disruption of cells. Dispense $75\mu\text{l}$ of ADCC Assay Buffer into those outermost wells, labeled “B” in Figure 7, of both assay plates. Cover the plates with lids, and keep the plates in a CO_2 incubator at 37°C before adding antibody dilutions and ADCC Bioassay Effector Cells.

5.D. Preparing Antibody Serial Dilutions

Preparing Serial Dilutions From a Single Antibody Dilution Stock to Generate Triplicates

Note: Alternatively, you can make three independent antibody dilution stocks to generate triplicates of each dose-response curve.

In order to establish a full dose-response range for any antibody to be tested in the ADCC Reporter Bioassay, we suggest that you first determine the starting concentrations and serial dilution schemes optimal for the antibody based on previous test results if possible (e.g., data from ADCC cytotoxicity assay). For your reference, when tested in ADCC Reporter Bioassay, the starting concentrations and serial dilution schemes are $1 \times 10^{-6}\text{g/ml}$, fourfold serial dilution for rituximab, and $1 \times 10^{-6}\text{g/ml}$, threefold serial dilution for trastuzumab. These provide full dose-response curves in both cases.

The instructions below are for generating threefold serial dilution series for the reference antibody and test antibodies and serve as an example dilution series. If different serial dilution schemes are needed, please adjust the volumes accordingly. If each of the antibodies requires a different dilution scheme, please make separate serial dilutions for each antibody. Prepare 100µl for each antibody dilution to provide sufficient volume for triplicates in the assay.

1. Obtain a sterile clear V-bottom 96-well plate for preparing antibody serial dilutions. For threefold serial dilutions, perform the dilutions described in Steps 2–8 below. You will need 400µl of reference antibody at 3X the highest antibody concentration in your dose-response curve. You will need 200µl of each test antibody at 3X the highest antibody concentration in each of their dose-response curves. Adjust all volumes accordingly for other dilution schemes.
2. Add 150µl of reference antibody starting dilution (dilu1, 3X final concentration) to both well A11 and well B11.
3. Add 150µl of test antibody 1 and 150µl of test antibody 2 starting dilution (dilu1, 3X final concentration) to well E11 and well G11, respectively (see Figure 8).
4. Add 100µl of ADCC Assay Buffer to other wells in these four rows, from column 10 to column 2.
5. Transfer 50µl from the antibody starting dilutions in column 11 into column 10. Mix well by pipetting. Avoid creating bubbles.
6. Repeat equivalent threefold serial dilutions across columns from right to left until you reach column 3.
Note: Wells A2, B2, E2 and G2 will contain 100µl of ADCC Assay Buffer as a “no-antibody” control.
7. Place the plate with antibody dilutions on the bench during preparation of ADCC Bioassay Effector Cells at the next step. Cover with a lid.

Recommended Plate Layout Antibody Dilutions Prepared from a Single Antibody Stock													
	1	2	3	4	5	6	7	8	9	10	11	12	
A		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Reference Ab
B		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Reference Ab
C													
D													
E		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Test Ab 1
F													
G		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Test Ab 2
H													

Figure 8. Example plate layout showing serial dilutions of antibodies. Reference and test antibodies for serial dilutions from a single antibody stock to generate triplicates.

5.E. Preparing ADCC Bioassay Effector Cells

You should grow ADCC Bioassay Effector Cells for use in the assay under the propagation protocol we recommend. Do not exceed the recommended maximum cell density, and adhere to the 2- to 3-day regimen for splitting and to the specified seeding density range for expansion. Use cells in assay only after cell doubling during propagation has stabilized. Stabilization after initial seeding should occur within 7 to 10 days. We recommend that you demonstrate stabilization across two consecutive doublings. Doubling rates of 24 hours $\pm$ 33% should be expected if you follow the propagation protocol. The propagation protocol provides assay consistency.

1. Transfer ADCC Bioassay Effector Cells from the propagation flask to a 50ml conical tube, and count the cells to determine cell density. Use Trypan Blue staining to evaluate cell viability. To ensure appropriate functional performance in the ADCC Reporter Bioassay, the ideal density upon harvest is $1.2\text{--}1.8 \times 10^6$ cells/ml, and the cell viability is greater than 95%.
2. Pellet cells at $130 \times g$ for 10 minutes at ambient temperature, wash cells with 10ml of 1X DPBS, and recentrifuge at $130 \times g$ for 10 minutes. Resuspend cells in ADCC Assay Buffer at 70% of full volume needed to generate a cell suspension at 6×10^6 cells/ml, based on the cell counts determined in Step 1.
3. Count the cells again to evaluate whether there has been any cell loss during the centrifugation. Adjust the volume of ADCC Assay Buffer based on the second cell count to make a final cell suspension at a density of 6×10^6 cells/ml.

5.F. Adding Antibody and ADCC Bioassay Effector Cells to Target Cells in Assay Plates

1. Using a multichannel pipette, add 25 μ l per well of the antibody dilution series from the antibody dilution plates you prepared in Section 5.D to the white, 96-well assay plates already containing target cells, according to the plate layout in Figure 7.
2. Transfer the ADCC Bioassay Effector cells prepared in Section 5.E to a sterile reagent reservoir. Using a multichannel pipette, plate 25 μ l of ADCC Bioassay Effector Cells to those wells in the assay plate already containing target cells and antibody to yield 150,000 ADCC Bioassay Effector Cells per well.
3. Cover the assay plate with a lid, and incubate the plate in a 37°C CO₂ tissue culture incubator for the recommended 16–24 hours.

5.G. Adding Bio-Glo™ Luciferase Assay Reagent

1. Remove assay plates from the 37°C incubator and equilibrate to ambient temperature (22–25°C) on the bench for 15 minutes.
2. Using a manual multichannel pipette, add 75 μ l of Bio-Glo™ Luciferase Assay Reagent to all the inner 60-wells of both assay plates; avoid creating any bubbles.
Note: Bio-Glo™ Luciferase Assay Reagent should be at ambient temperature when added.
3. Add 75 μ l of Bio-Glo™ Luciferase Assay Reagent to wells B1, C1 and D1 in each assay plate to determine plate background.
4. Incubate at ambient temperature for 5–30 minutes.
5. Measure luminescence using a plate reader with glow-type luminescence reading capabilities.

5.H. Data Analysis

1. Determine Plate Background by calculating the average RLU from wells B1, C1 and D1.
2. Calculate Fold of Induction = $\text{RLU (induced-background)} / \text{RLU (no antibody control-background)}$
Note: When calculating Fold of Induction, if the sample RLUs are equal to or greater than 100 times higher than the plate background RLU, there is no need to subtract plate background from sample RLU.
3. Graph data as RLU versus Log10 [antibody] and Fold of Induction versus Log10 [antibody]. Fit curves and determine EC_{50} of antibody response using appropriate curve fitting software (such as GraphPad Prism® software).

6. Troubleshooting

For questions not addressed here, please contact your local Promega Branch Office or Distributor. Contact information available at: www.promega.com. E-mail: techserv@promega.com

Symptoms	Possible Causes and Comments
High background	As a bioluminescent assay, the ADCC Reporter Bioassay generally gives low assay background and high signal response. There are multiple possible causes for high background such as a matrix effect from assay buffer or antibody stock solution, signal crosstalk from neighboring wells due to use of unsuitable assay plates or improper settings for the detection instrument. See also the “Possible issues with matrix effect” comments below.
Poor or low luminescence measurements (RLU readout)	Choose a sensitive instrument designed for luminescence detection. Instruments primarily designed for fluorescence detection are not recommended. Luminometers measure and report luminescence as relative values, and actual numbers will vary between instruments. See Before You Begin, Section 3, for more recommendations on how to set up the luminometer. If you must use an instrument primarily designed for fluorescence detection, ensure no filters are used. Insufficient effector cells could lead to low RLU. Handle and plate the effector cells appropriately according to the instructions in this protocol to ensure that there are sufficient, viable effector cells per well in the assay. Low activity of Bio-Glo™ Luciferase Assay Reagent also leads to low RLU. Store and handle Bio-Glo™ Luciferase Assay Reagent appropriately according to the instructions in the protocol. Weak ADCC response (see section below).

6. Troubleshooting (continued)

Symptoms

Possible Causes and Comments

Possible issues with matrix effect

IgG, serum complement or other components from serum, supernatant of phage display or hybridoma culture could nonspecifically impact antibody binding to the FcγRIIIa receptor or affect NFAT-RE signaling pathway directly, and cause a matrix effect. Use Low IgG Serum or perform further dilution of antibody starting preparation to minimize any matrix effect. The use of heat-inactivated or Low IgG Serum for growth of target cells also helps.

Weak ADCC response

Optimize the E:T ratio while keeping the effector cell number constant at 150,000 cells per well. Since the readout of the ADCC Reporter Bioassay is from the effector cells, improvement of the response can be achieved by increasing the number of target cells per well.

Make sure to use the optimal concentration range for the antibody, which can provide a full dose response with complete upper and lower asymptotes. Note that EC₅₀ of antibody in ADCC Reporter Bioassay is not necessarily the same as that from other ADCC bioassays, thus some adjustment on the antibody starting concentration and serial dilution schemes may be needed to achieve the maximal response in the ADCC Reporter Bioassay.

Optimize assay incubation time within a range of 6–24 hours, and choose the incubation time that gives optimal ADCC response.

Optimize the composition of ADCC Assay Buffer by varying the concentration of Low IgG FBS in a range of 0.5–10%, and choose the serum concentration that gives the optimal ADCC response.

Will I see the same ranking of therapeutic Abs in the Promega ADCC Reporter Bioassay as in a classic ADCC bioassay?

The ADCC Reporter Bioassay and classic ADCC assays show the same expected relative potency differences for Ab variants known to differ in ADCC efficiencies. This has been observed in several different studies using antibodies that differ in glycosylation, including fucosylation, and amino acid sequence. **Note:** Assays should be performed using conditions that can differentiate activities in the ranges expected. These conditions may not be the same or both assays.

Symptoms

EC₅₀ for Ab varies between classic and ADCC bioassay and Promega ADCC Reporter Bioassay

Possible Causes and Comments

EC₅₀ refers to the concentration of the substance (mAb in this assay) that gives 50% of the maximal biological response. The EC₅₀ value is determined not only by the binding affinity of the antibody but also by the assay conditions used in that particular assay such as the the E:T ratio, incubation time and assay buffer in the case of ADCC bioassays. The time and assay buffer in the case of ADCC bioassays. The EC₅₀ value of any antibody can differ dramatically between different assays and is not an intrinsic property of the antibody. It is normal if the EC₅₀ value for an Ab differs between ADCC Reporter Bioassay and other ADCC bioassays.

Viability of target cells or effector cells grown in continuous culture is low.

Note: Propagate and freeze the ADCC Bioassay Effector Cells in the exact manner described here. Keep the viability of your target cells and ADCC Bioassay Effector Cells high and constant. This provides the best inter-assay precision and consistent data for your reference antibody. Some dead cells are acceptable, and the assay response should be robust within a defined range of cell density and viability. Should a low number of viable cells be evident, do not use them because your assay performance will be compromised.

7. References

1. Hogarth, P.M. and Pietersz, G.A. (2012) Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. *Nat. Rev. Drug Discov.* **11**, 311–31.
2. Chung, S. *et al.* (2012) Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities. *mAbs* **4**, 326–40.
3. Parekh, B.S. *et al.* (2012) Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. *mAbs* **4**, 310–8.
4. Chung, S. *et al.* (2014) Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies — Impact of effector cells. *J. Immun. Methods* **407**, 63–75.
5. Cheng, Z.J. *et al.* (2014) Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. *J. Immun. Methods* **414**, 69–81.

8. Composition of Buffers and Media

Cell Growth Medium

90%	RPMI 1640 with L-glutamine
10%	FBS
100µg/ml	hygromycin
250µg/ml	Antibiotic G-418 Sulfate Solution
1mM	sodium pyruvate
0.1mM	MEM nonessential amino acids

Cell Freezing Medium

85%	RPMI 1640 with L-glutamine
10%	FBS
5%	DMSO

ADCC Assay Buffer

99.5%	RPMI 1640 with L-glutamine
0.5%	low IgG FBS

9. Appendix: Representative Assay Results

The following data were generated using the ADCC Bioassay Effector Cells, Propagation Model, with either suspension (Figure 9) or adherent target cells (Figure 10) grown in continuous culture prior to bioassay.




Figure 9. ADCC Reporter Bioassay response to rituximab (RITUXAN®) using ADCC Bioassay Effector Cells. CD20⁺ WIL2-S cells were harvested and plated in a 96-well white assay plate at 20,000 cells per well, followed by addition of a series of concentrations of rituximab. ADCC Bioassay Effector Cells (150,000 cells per well) were then added to the assay plate. After 20 hours of induction at 37°C, Bio-Glo™ Luciferase Assay Reagent was added, and luminescence was determined using a GloMax® Detection System. The data were fitted to a 4PL curve using GraphPad Prism® software.




Figure 10. ADCC Reporter Bioassay response to trastuzumab (trade name: HERCEPTIN®) using ADCC Bioassay Effector Cells. Her2⁺ SK-BR-3 cells were plated in 96-well assay plate at 10,000 cells per well in complete culture medium overnight before bioassay. On the day of assay, the culture medium was removed carefully and replaced with a series of concentrations of trastuzumab. After 5–10 minutes of incubation on the bench top, 150,000 cells per well of ADCC Bioassay Effector Cells were added to the assay plate already containing SK-BR-3 cells and antibody. After 20 hours of induction at 37°C, Bio-Glo™ Luciferase Assay Reagent was added and luminescence determined using a GloMax® Detection System. Data were fitted to a 4PL curve using GraphPad Prism® software

10. Related Products

ADCC Reporter Bioassays and Detection Reagent

Product	Size	Cat.#
ADCC Reporter Bioassay, Core Kit	1 each	G7010
ADCC Reporter Bioassay, Core Kit (5X)	1 each	G7018
ADCC Reporter Bioassay, Target Kit (WIL2-S)	1 each	G7013
ADCC Reporter Bioassay, Complete Kit (WIL2-S)	1 each	G7014
ADCC Reporter Bioassay, Target Kit (Raji)	1 each	G7016
ADCC Reporter Bioassay, Complete Kit (Raji)	1 each	G7015
Bio-Glo™ Luciferase Assay System*	100ml	G7940
	10ml	G7941



10. Related Products (continued)

Product	Size	Cat.#
ADCC Reporter Bioassay F Variant, Core Kit	1 each	G9790
ADCC Reporter Bioassay F Variant, Core Kit 5X	1 each	G9798
ADCC Reporter Bioassay F Variant, Propagation Model	1 each	G9302
mFc γ RIV ADCC Reporter Bioassay, Complete Kit	1 each	M1201
mFc γ RIV ADCC REporter Bioassay, Core Kit	1 each	M1211
mFc γ RIV ADCC Reporter Bioassay, Core Kit 5X	1 each	M1215
mFc γ RIV ADCC Reporter Bioassay, Propagation Model	1 each	M1212
Fc γ RIIa-H ADCP Reporter Bioassay, Complete Kit	1 each	G9901
Fc γ RIIa-H ADCP Reporter Bioassay, Core Kit	1 each	G9991
Fc γ RIIa-H ADCP Reporter Bioassay, Core Kit 5X	1 each	G9995
Fc γ RIIa-H ADCP Reporter Bioassay, Propagation Model	1 each	G9871

*Not for Medical Diagnostic Use.

Luminometers

PRODUCT	SIZE	CAT.#
GloMax [®] Navigator System	1 each	GM2000
GloMax [®] Discover System	1 each	GM3000
GloMax [®] Explorer System	1 each	GM3500

For Research Use Only. Not for use in diagnostic procedures.

Note: Additional Immunotherapy and Fc Effector Bioassays are available from Promega Custom Assay Services. To view and order products from Custom Assay Services visit: www.promega.com/CAS or email: CAS@promega.com

11. Summary of Changes

The following change was made to the 3/19 revision of this document:

1. Corrected the HyClone fetal bovine serum catalog number in Section 3.A.

^(a)NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.

This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) drug discovery and development of biologic drugs, (3) quality assurance testing of biologic drugs, and (4) product release assays for biologic drugs. No other commercial use is allowed. "Commercial use" means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to modify, derivatize, genetically engineer or otherwise create variations of the Effector Cells or the luciferase gene stably transfected within the Effector Cells, except that recipient may propagate and store Effector Cells for use in Antibody-Dependent Cell-Mediated Cytotoxicity assays. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all determinations of luminescence activity of this product, or contact Promega to obtain a license for use of this product with reagents other than Promega's. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

^(b)U.S. Pat. No. 8,008,006 and European Pat. No. 1341808.

^(c)Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.

© 2012–2016, 2018, 2019 Promega Corporation. All Rights Reserved.

CytoTox 96, GloMax and Instinct are registered trademarks of Promega Corporation. Bio-Glo is a trademark of Promega Corporation.

GraphPad Prism is a registered trademark of GraphPad Software, Inc. HERCEPTIN and RITUXAN are registered trademarks of Genentech USA, Inc. JMP is a registered trademark of SAS Institutes, Inc.

Products may be covered by pending or issued patents or may have certain limitations. Please visit our Web site for more information.

All prices and specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.